Evaluation of Neonatal and Paediatric Vancomycin Pharmacokinetic Models and the Impact of Maturation and Serum Creatinine Covariates in a Large Multicentre Data Set.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
20
10
2022
pubmed:
21
11
2022
medline:
8
2
2023
entrez:
20
11
2022
Statut:
ppublish
Résumé
Infants and neonates present a clinical challenge for dosing drugs with high interindividual variability due to these patients' rapid growth and the interplay between maturation and organ function. Model-informed precision dosing (MIPD), which can account for interindividual variability via patient characteristics and Bayesian forecasting, promises to improve individualized dosing strategies in this complex population. Here, we assess the predictive performance of published population pharmacokinetic models describing vancomycin in neonates and infants, and analyze the robustness of these models in the face of clinical uncertainty surrounding covariate values. The predictive precision and bias of nine pharmacokinetic models were compared in a large multi-site data set (N = 2061 patients, 5794 drug levels, 28 institutions) of patients aged 0-365 days. The robustness of model predictions to errors in serum creatinine measurements and gestational age was assessed by using recorded values or by replacing covariate values with 0.3, 0.5 or 0.8 mg/dL or with 40 weeks, respectively. Of the nine models, two models (Dao and Jacqz-Aigrain) resulted in predicted concentrations within 2.5 mg/L or 15% of the measured values for at least 60% of population predictions. Within individual models, predictive performance often 2 differed in neonates (0-4 weeks) versus older infants (15-52 weeks). For preterm neonates, imputing gestational age as 40 weeks reduced the accuracy of model predictions. Measured values of serum creatinine improved model predictions compared to using imputed values even in neonates ≤1 week of age. Several available pharmacokinetic models are suitable for MIPD in infants and neonates. Availability and accuracy of model covariates for patients will be important for guiding dose decision-making.
Sections du résumé
BACKGROUND AND OBJECTIVE
Infants and neonates present a clinical challenge for dosing drugs with high interindividual variability due to these patients' rapid growth and the interplay between maturation and organ function. Model-informed precision dosing (MIPD), which can account for interindividual variability via patient characteristics and Bayesian forecasting, promises to improve individualized dosing strategies in this complex population. Here, we assess the predictive performance of published population pharmacokinetic models describing vancomycin in neonates and infants, and analyze the robustness of these models in the face of clinical uncertainty surrounding covariate values.
METHODS
The predictive precision and bias of nine pharmacokinetic models were compared in a large multi-site data set (N = 2061 patients, 5794 drug levels, 28 institutions) of patients aged 0-365 days. The robustness of model predictions to errors in serum creatinine measurements and gestational age was assessed by using recorded values or by replacing covariate values with 0.3, 0.5 or 0.8 mg/dL or with 40 weeks, respectively.
RESULTS
Of the nine models, two models (Dao and Jacqz-Aigrain) resulted in predicted concentrations within 2.5 mg/L or 15% of the measured values for at least 60% of population predictions. Within individual models, predictive performance often 2 differed in neonates (0-4 weeks) versus older infants (15-52 weeks). For preterm neonates, imputing gestational age as 40 weeks reduced the accuracy of model predictions. Measured values of serum creatinine improved model predictions compared to using imputed values even in neonates ≤1 week of age.
CONCLUSIONS
Several available pharmacokinetic models are suitable for MIPD in infants and neonates. Availability and accuracy of model covariates for patients will be important for guiding dose decision-making.
Identifiants
pubmed: 36404388
doi: 10.1007/s40262-022-01185-4
pii: 10.1007/s40262-022-01185-4
pmc: PMC9898357
doi:
Substances chimiques
Vancomycin
6Q205EH1VU
Anti-Bacterial Agents
0
Creatinine
AYI8EX34EU
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-76Informations de copyright
© 2022. The Author(s).
Références
Acta Clin Belg. 2019 Jun;74(3):157-163
pubmed: 29745792
Annu Rev Pharmacol Toxicol. 2008;48:303-32
pubmed: 17914927
Ther Drug Monit. 2021 Feb 1;43(1):139-140
pubmed: 33009289
J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):262-76
pubmed: 25762871
Epidemiology. 2017 Nov;28(6):854-862
pubmed: 28692489
Neonatology. 2020;117(5):637-640
pubmed: 32961538
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2039-42
pubmed: 26787690
Pediatr Nephrol. 2021 Mar;36(3):649-659
pubmed: 32944826
PLoS One. 2018 May 24;13(5):e0196721
pubmed: 29795567
Clin Pharmacokinet. 2019 Jun;58(6):767-780
pubmed: 30656565
Clin Pharmacol Ther. 2021 Jan;109(1):233-242
pubmed: 33068298
CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1150-1160
pubmed: 34270885
J Antimicrob Chemother. 2019 Aug 1;74(8):2128-2138
pubmed: 31049551
J Clin Pharmacol. 2001 Sep;41(9):927-34
pubmed: 11549096
J Antimicrob Chemother. 2020 Nov 1;75(11):3293-3302
pubmed: 32790842
Br J Clin Pharmacol. 2007 Jan;63(1):75-84
pubmed: 16869817
J Antimicrob Chemother. 2020 Feb 1;75(2):434-437
pubmed: 31670812
Clin Biochem. 2011 Sep;44(13):1156-1159
pubmed: 21771588
Int J Antimicrob Agents. 2021 Mar;57(3):106300
pubmed: 33567334
CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):785-787
pubmed: 30255663
Clin Infect Dis. 2009 Aug 1;49(3):325-7
pubmed: 19569969
Antimicrob Agents Chemother. 2015 Oct;59(10):6344-51
pubmed: 26248375
Gynecol Obstet Invest. 1989;28(2):70-2
pubmed: 2792916
Pediatrics. 1999 Apr;103(4):e49
pubmed: 10103341
Curr Opin Pediatr. 2016 Apr;28(2):173-9
pubmed: 26766603
Pharmacol Res. 2020 Apr;154:104278
pubmed: 31108184
Ther Drug Monit. 2014 Aug;36(4):510-8
pubmed: 24452067
Pediatr Nephrol. 2021 Jun;36(6):1439-1446
pubmed: 32529323
J Clin Pharmacol. 2019 Feb;59(2):168-176
pubmed: 30204236
Ther Drug Monit. 2020 Oct;42(5):778-786
pubmed: 32427759
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30833429
J Pediatric Infect Dis Soc. 2019 May 11;8(2):97-104
pubmed: 29294072
Antimicrob Agents Chemother. 2014 Nov;58(11):6454-61
pubmed: 25136027
J Antimicrob Chemother. 2019 Apr 1;74(4):1003-1011
pubmed: 30668696
CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):711-720
pubmed: 35259285
Paediatr Perinat Epidemiol. 2007 Sep;21 Suppl 2:13-21
pubmed: 17803614